MovDisordV3, PascalFrancis, Corpus, bibRecord, 000F19

Funding of Parkinson Research from Industry and US Federal and Foundation Sources

Identifieur interne : 000F19 ( PascalFrancis/Corpus ); précédent : 000F18; suivant : 000F20

Funding of Parkinson Research from Industry and US Federal and Foundation Sources

Auteurs : E. Ray Dorsey ; Joel P. Thompson ; Mark Frasier ; Todd Sherer ; Brian Fiske ; Sean Nicholson ; S. Claiborne Johnston ; Robert G. Holloway ; Hamilton Iii Moses

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0218143

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Industrie.

English descriptors

KwdEn :
- Industry, Nervous system diseases, Parkinson disease.

Abstract

Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 24`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Funding of Parkinson Research from Industry and US Federal and Foundation Sources`
A11	`01`	`1`		`@1 DORSEY (E. Ray)`
A11	`02`	`1`		`@1 THOMPSON (Joel P.)`
A11	`03`	`1`		`@1 FRASIER (Mark)`
A11	`04`	`1`		`@1 SHERER (Todd)`
A11	`05`	`1`		`@1 FISKE (Brian)`
A11	`06`	`1`		`@1 NICHOLSON (Sean)`
A11	`07`	`1`		`@1 CLAIBORNE JOHNSTON (S.)`
A11	`08`	`1`		`@1 HOLLOWAY (Robert G.)`
A11	`09`	`1`		`@1 MOSES (Hamilton III)`
A14	`01`			`@1 Department of Neurology, University of Rochester Medical Center @2 Rochester, New York @3 USA @Z 1 aut. @Z 8 aut.`
A14	`02`			`@1 School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences @2 Buffalo, New York @3 USA @Z 2 aut.`
A14	`03`			`@1 Michael J. Fox Foundation for Parkinson's Research @2 New York, New York @3 USA @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A14	`04`			`@1 Department of Policy Analysis and Management, Cornell University @2 Ithaca, New York @3 USA @Z 6 aut.`
A14	`05`			`@1 Department of Neurology, University of California @2 San Francisco, California @3 USA @Z 7 aut.`
A14	`06`			`@1 The Alerion Institute @2 North Garden, Virginia @3 USA @Z 9 aut.`
A20				`@1 731-737`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000186090170150`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 36 ref.`
A47	`01`	`1`		`@0 09-0218143`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Industrie @5 09`
C03	`03`	`X`	`ENG`	`@0 Industry @5 09`
C03	`03`	`X`	`SPA`	`@0 Industria @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 159`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 09-0218143 INIST
ET :	Funding of Parkinson Research from Industry and US Federal and Foundation Sources
AU :	DORSEY (E. Ray); THOMPSON (Joel P.); FRASIER (Mark); SHERER (Todd); FISKE (Brian); NICHOLSON (Sean); CLAIBORNE JOHNSTON (S.); HOLLOWAY (Robert G.); MOSES (Hamilton III)
AF :	Department of Neurology, University of Rochester Medical Center/Rochester, New York/Etats-Unis (1 aut., 8 aut.); School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences/Buffalo, New York/Etats-Unis (2 aut.); Michael J. Fox Foundation for Parkinson's Research/New York, New York/Etats-Unis (3 aut., 4 aut., 5 aut.); Department of Policy Analysis and Management, Cornell University/Ithaca, New York/Etats-Unis (6 aut.); Department of Neurology, University of California/San Francisco, California/Etats-Unis (7 aut.); The Alerion Institute/North Garden, Virginia/Etats-Unis (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 5; Pp. 731-737; Bibl. 36 ref.
LA :	Anglais
EA :	Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Industrie
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Industry
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Industria
LO :	INIST-20953.354000186090170150
ID :	09-0218143

Links to Exploration step

Pascal:09-0218143

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Funding of Parkinson Research from Industry and US Federal and Foundation Sources</title>
<author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name>
<affiliation><inist:fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1>
<s2>Ithaca, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Claiborne Johnston, S" sort="Claiborne Johnston, S" uniqKey="Claiborne Johnston S" first="S." last="Claiborne Johnston">S. Claiborne Johnston</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moses, Hamilton Iii" sort="Moses, Hamilton Iii" uniqKey="Moses H" first="Hamilton Iii" last="Moses">Hamilton Iii Moses</name>
<affiliation><inist:fA14 i1="06"><s1>The Alerion Institute</s1>
<s2>North Garden, Virginia</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0218143</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0218143 INIST</idno>
<idno type="RBID">Pascal:09-0218143</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F19</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Funding of Parkinson Research from Industry and US Federal and Foundation Sources</title>
<author><name sortKey="Dorsey, E Ray" sort="Dorsey, E Ray" uniqKey="Dorsey E" first="E. Ray" last="Dorsey">E. Ray Dorsey</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Thompson, Joel P" sort="Thompson, Joel P" uniqKey="Thompson J" first="Joel P." last="Thompson">Joel P. Thompson</name>
<affiliation><inist:fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frasier, Mark" sort="Frasier, Mark" uniqKey="Frasier M" first="Mark" last="Frasier">Mark Frasier</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sherer, Todd" sort="Sherer, Todd" uniqKey="Sherer T" first="Todd" last="Sherer">Todd Sherer</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fiske, Brian" sort="Fiske, Brian" uniqKey="Fiske B" first="Brian" last="Fiske">Brian Fiske</name>
<affiliation><inist:fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nicholson, Sean" sort="Nicholson, Sean" uniqKey="Nicholson S" first="Sean" last="Nicholson">Sean Nicholson</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1>
<s2>Ithaca, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Claiborne Johnston, S" sort="Claiborne Johnston, S" uniqKey="Claiborne Johnston S" first="S." last="Claiborne Johnston">S. Claiborne Johnston</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holloway, Robert G" sort="Holloway, Robert G" uniqKey="Holloway R" first="Robert G." last="Holloway">Robert G. Holloway</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Moses, Hamilton Iii" sort="Moses, Hamilton Iii" uniqKey="Moses H" first="Hamilton Iii" last="Moses">Hamilton Iii Moses</name>
<affiliation><inist:fA14 i1="06"><s1>The Alerion Institute</s1>
<s2>North Garden, Virginia</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Industry</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Industrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>24</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Funding of Parkinson Research from Industry and US Federal and Foundation Sources</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DORSEY (E. Ray)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>THOMPSON (Joel P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FRASIER (Mark)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SHERER (Todd)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FISKE (Brian)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NICHOLSON (Sean)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CLAIBORNE JOHNSTON (S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>HOLLOWAY (Robert G.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MOSES (Hamilton III)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University of Rochester Medical Center</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences</s1>
<s2>Buffalo, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Michael J. Fox Foundation for Parkinson's Research</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Policy Analysis and Management, Cornell University</s1>
<s2>Ithaca, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>The Alerion Institute</s1>
<s2>North Garden, Virginia</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>731-737</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000186090170150</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>36 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0218143</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Industrie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Industry</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Industria</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>159</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 09-0218143 INIST</NO>
<ET>Funding of Parkinson Research from Industry and US Federal and Foundation Sources</ET>
<AU>DORSEY (E. Ray); THOMPSON (Joel P.); FRASIER (Mark); SHERER (Todd); FISKE (Brian); NICHOLSON (Sean); CLAIBORNE JOHNSTON (S.); HOLLOWAY (Robert G.); MOSES (Hamilton III)</AU>
<AF>Department of Neurology, University of Rochester Medical Center/Rochester, New York/Etats-Unis (1 aut., 8 aut.); School of Medicine, University at Buffalo School of Medicine & Biomedical Sciences/Buffalo, New York/Etats-Unis (2 aut.); Michael J. Fox Foundation for Parkinson's Research/New York, New York/Etats-Unis (3 aut., 4 aut., 5 aut.); Department of Policy Analysis and Management, Cornell University/Ithaca, New York/Etats-Unis (6 aut.); Department of Neurology, University of California/San Francisco, California/Etats-Unis (7 aut.); The Alerion Institute/North Garden, Virginia/Etats-Unis (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 5; Pp. 731-737; Bibl. 36 ref.</SO>
<LA>Anglais</LA>
<EA>Funding for biomedical and neuroscience research has increased over the last decade but without a concomitant increase in new therapies. This study's objectives were to determine the level and principal sources of recent funding for Parkinson disease (PD) research and to determine the current state of PD drug development. We determined the level and principal sources of recent funding for PD research from the following sources: US federal agencies, large PD foundations based in the United States, and global industry. We assessed the status of PD drug development through the use of a proprietary drug pipeline database. Funding for PD research from the sources examined was approximately $1.1 billion in 2003 and $1.2 billion in 2005. Industry accounted for 77% of support from 2003 to 2005. The number of drugs in development for PD increased from 67 in 2003 to 97 in 2007. Of the companies with at least one compound in development for PD in 2007, most were small (62% had annual revenue of less than $100 million), and most (53%) were based outside the United States. These companies will likely require partnerships to drive successful development of new PD therapies.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Industrie</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Industry</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Industria</SD>
<LO>INIST-20953.354000186090170150</LO>
<ID>09-0218143</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F19 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000F19 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0218143
   |texte=   Funding of Parkinson Research from Industry and US Federal and Foundation Sources
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Funding of Parkinson Research from Industry and US Federal and Foundation Sources

Funding of Parkinson Research from Industry and US Federal and Foundation Sources

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri